Prilenia Therapeutics to fund late-stage clinical trials in HD and ALS
Clinical stage biotechnology firm Prilenia Therapeutics has raised $62.5m through a Series A financing round...
Read More...
Focus:
Israel
-
![MGC; ArtemiC]()
MGC begins Phase II study of ArtemiC to treat Covid-19
MGC Pharmaceuticals has started a Phase II clinical trial of ArtemiC for the treatment of...
Read More...
-
![MGC; ArtemiC]()
MGC receives second approval for Covid-19 trial in Israel
MGC Pharmaceuticals has received a second human research ethics committee approval in Israel to conduct...
Read More...
-
![]()
Initial data shows improvement in Covid-19 with RedHill’s opaganib
RedHill Biopharma has reported preliminary data from a compassionate use programme of opaganib (Yeliva, ABC294640)...
Read More...
-
![Pluristem begins dosing with Covid-19 therapy in Israel]()
Pluristem begins dosing with Covid-19 therapy in Israel
Pluristem Therapeutics has started dosing Covid-19 patients in Israel with PLX cells under a compassionate...
Read More...
-
![]()
VBL Therapeutics initiates VB-111’s trial in colorectal cancer
VBL Therapeutics has initiated a Phase II clinical trial of a VB-111 and Opdivo (nivolumab)...
Read More...
-
![]()
Teva’s deutetrabenazine fails in paediatric Tourette syndrome trials
Results from Teva Pharmaceutical Industries have revealed that deutetrabenazine did not meet the primary endpoint...
Read More...
-
![]()
Ovid is considering expanding Phase III trial size of gaboxadol in Angelman syndrome
Ovid Therapeutics is considering potentially increasing the size of its Phase III gaboxadol trial in Angelman syndrome (AS) given global…
Read More…
-
![]()
VBL Therapeutics publishes Phase II and III data of VB-111
VBL Therapeutics, a clinical biopharmaceutical firm engaged in developing cancer treatments, has published clinical data...
Read More...
-
Therapix’s THX-110 shows positive results in OSA patients
Therapix Biosciences has announced that investigational drug THX-110 yielded favourable data in a Phase IIa...
Read More...